The company's Dragonfly instrument uses a proprietary sample preparation method and isothermal amplification to diagnose a variety of infectious diseases.

The projects include the development of rapid diagnostic tests for tuberculosis, Strongyloides stercoralis, and malaria.

The company is developing blood tests for chronic diseases using artificial intelligence models and a database of more than 400,000 tissue samples.

The partners will begin with work on a cortisol biosensor that can be used for stress and metabolic health testing.

The high-throughput antigen test includes all four dengue virus serotypes and returns results in about 18 minutes.

The companies will use the Phase I Small Business Innovation Research (SBIR) grant to support the development of a urine-based ELISA to inform treatment decisions.

Total revenues for the three months ended Sept. 30 were $3.56 billion, up from $3.28 billion in the third quarter of 2024 and matching the consensus Wall Street estimate.

Last week, readers were most interested in a story about Hologic's plans to go private via an acquisition by two private equity firms.

Diagnostics' products, including its in-development point-of-care molecular diagnostics system, in Saudi Arabia and 18 other MENA countries.

The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

The firm posted 2 percent overall revenue growth as strength in Europe and the Americas was offset by softness in China and the rest of Asia.